source
- Definium's LSD-based therapy shows strong Phase 3 results in generalized anxiety disorderDefinium Therapeutics reported that its LSD-derived oral tablet, DT120, met its primary endpoint in a Phase 3 trial for generalized anxiety disorder. The study enrolled over 200 participants and co…
- Eli Lilly fronts $2 billion for vaccine biotech deals as Infinimmune secures $75 million fundingEli Lilly announced it has paid $2 billion up front as part of its ongoing strategy to acquire vaccine‑focused biotechnology companies, a portion of a larger deal that could total up to $3.8 billio…